Omnicell, Inc. (NASDAQ:OMCL) Shares Acquired by Wells Fargo & Company MN

Wells Fargo & Company MN boosted its position in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 27.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 132,252 shares of the company's stock after acquiring an additional 28,390 shares during the period. Wells Fargo & Company MN owned 0.29% of Omnicell worth $5,888,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC raised its stake in Omnicell by 51.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock worth $35,000 after acquiring an additional 273 shares during the period. Van ECK Associates Corp raised its position in shares of Omnicell by 47.0% during the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company's stock valued at $44,000 after buying an additional 315 shares during the last quarter. First Horizon Advisors Inc. raised its position in shares of Omnicell by 36.3% during the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock valued at $59,000 after buying an additional 355 shares during the last quarter. Redmond Asset Management LLC raised its position in shares of Omnicell by 0.3% during the fourth quarter. Redmond Asset Management LLC now owns 121,209 shares of the company's stock valued at $5,396,000 after buying an additional 371 shares during the last quarter. Finally, Hillsdale Investment Management Inc. increased its position in Omnicell by 0.5% in the fourth quarter. Hillsdale Investment Management Inc. now owns 92,897 shares of the company's stock worth $4,136,000 after purchasing an additional 420 shares during the last quarter. Institutional investors own 97.70% of the company's stock.

Analysts Set New Price Targets

Several research analysts have commented on OMCL shares. Bank of America dropped their price objective on shares of Omnicell from $54.00 to $46.00 and set a "neutral" rating for the company in a research note on Monday, January 6th. StockNews.com raised shares of Omnicell from a "hold" rating to a "buy" rating in a research report on Tuesday, April 15th. Wells Fargo & Company reduced their target price on shares of Omnicell from $40.00 to $38.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 17th. Benchmark reaffirmed a "buy" rating and set a $62.00 target price on shares of Omnicell in a research report on Tuesday, February 4th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a research report on Thursday, March 20th. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $50.67.

Omnicell Trading Up 0.2 %

Omnicell stock traded up $0.07 during trading on Thursday, reaching $30.76. 40,370 shares of the company were exchanged, compared to its average volume of 534,290. Omnicell, Inc. has a 52-week low of $25.12 and a 52-week high of $55.75. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22. The stock's 50 day simple moving average is $34.67 and its two-hundred day simple moving average is $41.03. The company has a market capitalization of $1.44 billion, a P/E ratio of 113.98, a PEG ratio of 7.53 and a beta of 0.78.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. On average, equities research analysts expect that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.